Related Experiment Video
Updated: Apr 3, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism
Tammy Hennika1, Oren J Becher2
1Department of Pediatrics Duke University Medical Center, Durham, NC, USA Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Insights
Diffuse intrinsic pontine glioma (DIPG) is a deadly childhood brain cancer with poor survival rates. New genetic discoveries offer hope for targeted therapies beyond current radiation treatments.
Area of Science:
- Pediatric oncology
- Neuro-oncology
- Cancer genomics
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive and lethal pediatric brain tumor originating in the pons.
- Current standard treatment, focal radiation therapy, offers only transient palliation with a median survival of less than one year.
- Over three decades, there has been no significant improvement in survival rates for DIPG patients.
Observation:
- Recent genomic studies have identified specific mutations in DIPG tumors.
- K27M H3.3/H3.1 mutations are found in 80% of DIPG cases.
- ACVR1 mutations are present in 25% of diffuse intrinsic pontine gliomas.
Findings:
- The discovery of K27M and ACVR1 mutations provides crucial molecular targets for therapeutic development.
- Stereotactic tumor biopsies are safe and increasingly utilized in diagnostic protocols.
- Biopsies are now integrated into prospective clinical trials for DIPG.
Implications:
- These genetic findings open new avenues for developing targeted therapies against DIPG.
- Improved diagnostic strategies, including safe biopsy procedures, enhance patient stratification for clinical trials.
- Future research directions focus on leveraging molecular insights for novel, effective treatments for this devastating childhood cancer.
Abstract:
Diffuse intrinsic pontine glioma is a lethal brain cancer that arises in the pons of children. The median survival for children with diffuse intrinsic pontine glioma is less than 1 year from diagnosis, and no improvement in survival has been realized in more than 30 years. Currently, the standard of care for diffuse intrinsic pontine glioma is focal radiation therapy, which provides only temporary relief. Recent genomic analysis of tumors from biopsies and autopsies, have resulted in the discovery of K27M H3.3/H3.1 mutations in 80% and ACVR1 mutations in 25% of diffuse intrinsic pontine gliomas, providing renewed hope for future success in identifying effective therapies. In addition, as stereotactic tumor biopsies at diagnosis at specialized centers have been demonstrated to be safe, biopsies have now been incorporated into several prospective clinical trials. This article summarizes the epidemiology, clinical presentation, diagnosis, prognosis, molecular genetics, current treatment, and future therapeutic directions for diffuse intrinsic pontine glioma.
